KF-20444

• Description :

  KF-20444 is an orally active ALK inhibitor with blood-brain barrier penetration. KF-20444 exhibits strong inhibitory activity against ALK fusion proteins (EML4-ALK) and ALK resistance mutations (including L1196M, G1202R, and F1174L) . KF-20444 effectively suppresses the phosphorylation of ALK in ALK-driven cancer cell lines, thereby inhibiting cancer cell proliferation and inducing apoptosis. KF-20444 demonstrates anti-tumor efficacy in mouse models bearing ALK-positive non-small cell lung cancer (NSCLC) or neuroblastoma. KF-20444 can be used for the study of ALK-driven malignancies[1].

• CAS Number :

  [154015-73-3]

• UNSPSC :

  12352005

• Target :

  Anaplastic lymphoma kinase (ALK) ; Apoptosis

• Related Pathways :

  Apoptosis; Protein Tyrosine Kinase/RTK

• Field of Research :

  Cancer

• Smiles :

  O=C(C1=C2CCCC3=C(C=CC(C4=C(F)C=CC=C4)=C3)C2=NC5=C1C=C(C=C5)F)O

• Molecular Formula :

  C25H17F2NO2

• Molecular Weight :

  401.40

• References & Citations :

  [1]Kobayashi K, et al. Anti-arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis. Inflamm Res. 2001 Jan;50 (1) :24-31.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported